Research Article
Portal Vein Embolization with PVA and Coils before Major Hepatectomy: Single-Center Retrospective Analysis in Sixty-Four Patients
Table 1
Patients’ characteristics.
| | Number of patients | 64 | | Age, mean (SD) | 63.84 (11.56) | | Sex, N (%) | | | Female | 19 (29.69) | | Male | 45 (70.31) | | Tumor type, N (%) | | | Hepatocellular carcinoma | 4 (6.25) | | Colangiocarcinoma | 12 (18.75) | | Colorectal metastases | 47 (73.44) | | Hydatid cyst | 1 (1.56) | | Cirrhosis, N (%) | | | Absent | 62 (96.88) | | Present | 2 (3.12) | | Cirrhosis etiology, N (%) | | | HCV | 1 (1.56) | | None identified | 63 (98.44) | | Chemo before PVE, N (%) | | | No | 23 (35.94) | | Yes | 41 (64.06) | | Type of systemic chemotherapy, N (%) | | | FOLFIRI | 9 (23.08) | | FOLFIRI + bevacizumab | 2 (5.13) | | FOLFIRI + cetuximab | 5 (12.82) | | FOLFIRI + panitumumab | 1 (2.56) | | FOLFIRINOX | 1 (2.56) | | FOLFOX | 6 (15.38) | | FOLFOX + bevacisumab | 2 (5.13) | | FOLFOX + cetuximab | 2 (5.13) | | FOLFOX + folfirinox | 1 (2.56) | | FOLFOX + folfirinox + cetuximab | 1 (2.56) | | XELOX + cetuximab | 1 (2.56) | | XELIRI | 1 (2.56) | | Xeloda + FOLFIRI + erbitux | 1 (2.56) | | XELOX | 3 (7.69) | | XELOX + bevacizumab | 2 (5.13) | | XELOX + XELIRI | 1 (2.56) | | Chemo cycles, mean (SD) | 3.38 (4.36) | | Biliary drainage before PVE, N (%) | | | No | 63 (98.44) | | Yes | 1 (1.56) | | Arterial embolization, N (%) | | | No | 64 (100) |
|
|
HCV: hepatitis C virus; PVE: portal vein embolization.
|
